Using human prostate-specific antigen (PSA, a biomarker of prostate cancer) as a model disease biomarker, the Au@Pt NPs-based LFA achieved a low “naked eye” detection limit of 20 pg/mL, which was two orders of magnitude lower than that of conventional Au NPs-based LFA. The gene discussed is KLK3; the disease is prostate carcinoma.